| Talal Al Quraini, MD | |
|
751 Medical Center Ct, Chula Vista, CA 91911-6617 | |
| (619) 482-5825 | |
| Not Available |
| Full Name | Talal Al Quraini |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 52 Years |
| Location | 751 Medical Center Ct, Chula Vista, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316955446 | NPI | - | NPPES |
| 1316955446 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207PE0004X | Emergency Medicine - Emergency Medical Services | A61433 (California) | Primary |
| Entity Name | Desert Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114918612 PECOS PAC ID: 8123930427 Enrollment ID: O20031229000246 |
News Archive
An international medical conference here heard that an Australian developed anti-cancer therapy based on the use of a common cold virus to control cancer cell growth has begun safety testing in human subjects.
In President Obama's push for health reform, "new fault lines are opening up everywhere you look. Liberals are worried that Obama is going squishy on including a strong, government-run 'public option' among the health-care choices available to Americans.
The most commonly diagnosed form of breast cancer, termed estrogen receptor positive or ER+, accounts for the largest percentage of breast cancer deaths each year. Research by scientists at the HudsonAlpha Institute for Biotechnology and the University of Alabama at Birmingham Comprehensive Cancer Center aims to provide physicians a more targeted approach to treating ER+ breast cancer.
A new study from Cincinnati Children's Hospital Medical Center reports that beverage can stay-tabs pose a potential ingestion risk. In the 1970s, U.S. manufacturers switched to the stay-tab design after safety concerns about pull-tabs. The new study found 19 cases of stay-tab ingestion at a single institution, mainly among teenagers.
Sanofi and MannKind Corporation announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.
› Verified 6 days ago
| Entity Name | Marque Medical Clinic, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538466107 PECOS PAC ID: 9537345665 Enrollment ID: O20110525000301 |
News Archive
An international medical conference here heard that an Australian developed anti-cancer therapy based on the use of a common cold virus to control cancer cell growth has begun safety testing in human subjects.
In President Obama's push for health reform, "new fault lines are opening up everywhere you look. Liberals are worried that Obama is going squishy on including a strong, government-run 'public option' among the health-care choices available to Americans.
The most commonly diagnosed form of breast cancer, termed estrogen receptor positive or ER+, accounts for the largest percentage of breast cancer deaths each year. Research by scientists at the HudsonAlpha Institute for Biotechnology and the University of Alabama at Birmingham Comprehensive Cancer Center aims to provide physicians a more targeted approach to treating ER+ breast cancer.
A new study from Cincinnati Children's Hospital Medical Center reports that beverage can stay-tabs pose a potential ingestion risk. In the 1970s, U.S. manufacturers switched to the stay-tab design after safety concerns about pull-tabs. The new study found 19 cases of stay-tab ingestion at a single institution, mainly among teenagers.
Sanofi and MannKind Corporation announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.
› Verified 6 days ago
| Entity Name | La Jolla Emergency Enterprises, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447532650 PECOS PAC ID: 9537327374 Enrollment ID: O20120223000995 |
News Archive
An international medical conference here heard that an Australian developed anti-cancer therapy based on the use of a common cold virus to control cancer cell growth has begun safety testing in human subjects.
In President Obama's push for health reform, "new fault lines are opening up everywhere you look. Liberals are worried that Obama is going squishy on including a strong, government-run 'public option' among the health-care choices available to Americans.
The most commonly diagnosed form of breast cancer, termed estrogen receptor positive or ER+, accounts for the largest percentage of breast cancer deaths each year. Research by scientists at the HudsonAlpha Institute for Biotechnology and the University of Alabama at Birmingham Comprehensive Cancer Center aims to provide physicians a more targeted approach to treating ER+ breast cancer.
A new study from Cincinnati Children's Hospital Medical Center reports that beverage can stay-tabs pose a potential ingestion risk. In the 1970s, U.S. manufacturers switched to the stay-tab design after safety concerns about pull-tabs. The new study found 19 cases of stay-tab ingestion at a single institution, mainly among teenagers.
Sanofi and MannKind Corporation announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Talal Al Quraini, MD 2525 Ridgegate Row, Suite 900, La Jolla, CA 92037-0930 Ph: (858) 361-8004 | Talal Al Quraini, MD 751 Medical Center Ct, Chula Vista, CA 91911-6617 Ph: (619) 482-5825 |
News Archive
An international medical conference here heard that an Australian developed anti-cancer therapy based on the use of a common cold virus to control cancer cell growth has begun safety testing in human subjects.
In President Obama's push for health reform, "new fault lines are opening up everywhere you look. Liberals are worried that Obama is going squishy on including a strong, government-run 'public option' among the health-care choices available to Americans.
The most commonly diagnosed form of breast cancer, termed estrogen receptor positive or ER+, accounts for the largest percentage of breast cancer deaths each year. Research by scientists at the HudsonAlpha Institute for Biotechnology and the University of Alabama at Birmingham Comprehensive Cancer Center aims to provide physicians a more targeted approach to treating ER+ breast cancer.
A new study from Cincinnati Children's Hospital Medical Center reports that beverage can stay-tabs pose a potential ingestion risk. In the 1970s, U.S. manufacturers switched to the stay-tab design after safety concerns about pull-tabs. The new study found 19 cases of stay-tab ingestion at a single institution, mainly among teenagers.
Sanofi and MannKind Corporation announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.
› Verified 6 days ago
Dr. David Lee Vandenberg, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 435 H St, Chula Vista, CA 91910 Phone: 619-691-7290 Fax: 619-691-7432 | |
Dr. Christy Rosa Mohler, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 435 H St, Chula Vista, CA 91910 Phone: 619-691-7290 Fax: 619-691-7432 | |
Jeffrey Scott Overcash, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 752 Medical Center Ct, Suite 105, Chula Vista, CA 91911 Phone: 619-955-5246 Fax: 619-656-9761 | |
Dr. John A. Siefert, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 435 H St, Chula Vista, CA 91910 Phone: 619-691-7290 | |
Dr. Chad Michael Baasen, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 435 H St, Chula Vista, CA 91910 Phone: 760-725-1614 | |
Kevin Bernard Calhoun, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 751 Medical Center Ct, Chula Vista, CA 91911 Phone: 619-482-5825 | |
Dr. Karrar H. Ali, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 751 Medical Center Ct, Chula Vista, CA 91911 Phone: 619-502-3477 |